title: [Adjuvant treatment for stage I of testicular germ cell tumours].
abstract: BACKGROUND
  Testicular germ cell tumors (TGCT) are the most frequent malignancy seen in young men. More than 95% of patients diagnosed with early stage TGCT are cured. In management of stage I seminoma there are several treatment options, including adjuvant radiotherapy, adjuvant chemotherapy with one cycle of carboplatin or surveillance. Patients with stage I nonseminoma are treated with adjuvant chemotherapy, with nerve sparing retroperitoneal lymph node dissection or surveillance being considered another treatment alternatives for stage I disease.
  
  
  RESULTS
  Fifty five patients with stage I TGCT were diagnosed and treated in Masaryk Memorial Cancer Institute between January 2000 to December 2004. In a retrospective analysis, we reviewed treatment outcome and treatment strategy used in these patients. Patients characteristics also included histological subtype, risk status, age at the time of diagnosis, relapse rate, delayed toxicity, etc. Despite the small number of patients included in the analysis (55), there was observed a clear preference toward adjuvant radiotherapy in seminoma patients (95%) and adjuvant chemotherapy in nonseminoma patients (97%). During median follow up (5,6 years in seminoma group, 5,7 years in nonseminoma group) only two patients experienced relapse of disease in the seminoma group and none in the nonseminoma group. One patient died of metastatic colorectal cancer. Acute toxicity was acceptable, with no treatment related death. The long- term side effects were not significant (no grade 3 or 4 toxicity).
  
  
  CONCLUSIONS
  The achieved cure rates were high, with acceptable toxicity. The role of adjuvant chemotherapy with carboplatin in stage I seminoma remains controversial. Further management of TGCT should be guided by complete and correct assessment of known risk factors to ensure the potential for cure.
authors.affiliation: Klinika Komplexní Onkologické Péce, Masarykův Onkologický Ustav, Brno. lakomy@mou.cz
authors.forename: R
authors.initials: R
authors.lastname: Lakomý
authors.forename: A
authors.initials: A
authors.lastname: Poprach
authors.forename: R
authors.initials: R
authors.lastname: Nēmecek
authors.forename: J
authors.initials: J
authors.lastname: Vyskocil
authors.forename: B
authors.initials: B
authors.lastname: Ondrová
authors.forename: I
authors.initials: I
authors.lastname: Kocák
authors.forename: I
authors.initials: I
authors.lastname: Kocáková
authors.forename: Z
authors.initials: Z
authors.lastname: Rehák
authors.forename: R
authors.initials: R
authors.lastname: Vyzula
mesh_terms: D000293:Adolescent; D000328:Adult; D017024:Chemotherapy, Adjuvant; D006801:Humans; D008297:Male; D008875:Middle Aged; D018714:Radiotherapy, Adjuvant; D018239:Seminoma / Q000628:therapy*; D013736:Testicular Neoplasms / Q000628:therapy*; D055815:Young Adult